Tirzepatide when you have prediabetes and excess weight

What prediabetes means

Prediabetes means your blood sugar is higher than normal but not yet in the diabetes range. By hemoglobin A1C, the CDC defines normal as below 5.7%, prediabetes as 5.7% to 6.4% and diabetes as 6.5% or higher. Fasting glucose and glucose tolerance tests are also used.

The CDC estimates that more than 2 in 5 American adults have prediabetes, and many do not know it. It raises the risk of type 2 diabetes, heart disease and stroke. Being 45 or older, having overweight and a family history of diabetes are all reasons to get tested.

A1C is not perfect

A1C reflects average blood sugar over roughly three months, but some conditions can skew it. The CDC notes that severe anemia, kidney failure, liver disease, some blood disorders, recent blood loss or transfusion and some medicines can make results falsely high or low. Your clinician may pair A1C with fasting glucose or other tests to get a clearer picture.

What the three-year tirzepatide trial found

SURMOUNT-1 tested weekly tirzepatide against placebo in adults with obesity or overweight. Participants who also had prediabetes at the start continued for about three years. The results, published in the New England Journal of Medicine in 2025, showed sustained weight loss and a large reduction in the number of people who progressed to type 2 diabetes compared with placebo.

A 2026 follow-up analysis of the same group found that most participants on tirzepatide had limited weight regain after reaching their lowest weight, with lasting improvements in blood sugar while they stayed on treatment.

Two caveats matter. First, these were trials of branded tirzepatide with structured lifestyle support. Second, the benefits were measured while people stayed on treatment. Weight-loss medicines generally work only as long as they are taken, so stopping deserves a plan rather than an abrupt halt.

How it compares with lifestyle change and metformin

The landmark Diabetes Prevention Program found that a structured lifestyle program lowered the risk of type 2 diabetes by 58% over about three years, and by 71% in people 60 and older. Metformin lowered it by 31%, working best in people aged 25 to 44, those with a BMI of 35 or higher and women with past gestational diabetes.

Long-term follow-up showed the effects narrowing but persisting: after 15 years, the lifestyle group's diabetes risk was 27% lower than placebo and metformin's was 18% lower. The CDC's target for the lifestyle program is modest: lose about 5% to 7% of body weight and build up to 150 minutes a week of brisk activity.

These studies were not head-to-head with tirzepatide, so you cannot directly rank the options. Tirzepatide produces much more weight loss than lifestyle programs or metformin typically do, but it costs more, has more side effects and needs to be continued.

Who tirzepatide may suit

• Adults with prediabetes who also have obesity, or overweight with weight-related health problems.
• People who have tried a structured lifestyle approach and not reached their goals.
• People whose A1C or fasting glucose is drifting upward despite effort.
• Not a fit for people with normal weight and prediabetes, where lifestyle change and sometimes metformin are the usual tools.
• Not for anyone with a personal or family history of medullary thyroid carcinoma or MEN 2, or who is pregnant or planning pregnancy.

Safety to discuss first

Tirzepatide's label has a boxed warning about thyroid C-cell tumors seen in rats; it is unknown whether this happens in people. Common side effects are nausea, diarrhea, vomiting and constipation, especially after dose increases. Other warnings include pancreatitis, gallbladder disease, kidney injury from dehydration and low blood sugar with insulin or sulfonylureas. It can make birth control pills less reliable for four weeks after starting and after each dose increase.

Testing and pricing at HealifyMD

Before starting, your clinician usually checks A1C, fasting glucose, kidney and liver function and lipids; our comprehensive lab panel is $199. Rechecking A1C after a few months shows whether the plan is working. If you prefer to start with metformin, HealifyMD offers it at $149 for 3 months ($50/month).

Compounded tirzepatide is from $399/month, or $750 for 2 months ($375/month), confirmed at the eligibility review. It is not FDA-approved, has not been reviewed by the FDA for safety, effectiveness or quality, is not equivalent to Zepbound and was not part of the diabetes-prevention trials.